VCYT
Veracyte, Inc.
Diagnostics & Research · Healthcare · United States
52.17
close · 2026-10-29
value
54
cheaper than peers54
quality
90
stronger fundamentals90
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to book | 3.02× | 74 |
| forward P/E | 26.85× | 68 |
| EV to EBITDA | 27.84× | 38 |
| price to sales | 6.64× | 37 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.9% | 95 |
| operating margin | 15.3% | 72 |
| return on equity | 8.8% | 64 |
| revenue growth | 15.5% | 60 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $106.2M |
| employees | 755 |
| first trade | 2013-10-30 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.82 | 0.31 | -1.02 | -0.51 |
| free cash flow | $126.6M | $63.8M | $34.3M | -$1.0M |
| net income | $66.4M | $24.1M | -$74.4M | -$36.6M |
| revenue | $517.1M | $445.8M | $361.1M | $296.5M |
| unusual items | -$23.2M | -$5.4M | -$67.6M | -$3.1M |